SCHEMBL5541758

SCHEMBL5541758

CCCc1ccc2sc([O])nc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.45
NPC1 O15118 8/20 0.39
RAB9A P51151 8/20 0.39
SMN1; SMN2 Q16637 6/20 0.39
NFKB1 P19838 3/20 0.39
NFKB2 Q00653 3/20 0.39
RELA Q04206 3/20 0.39
PKM P14618 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 2/20 0.38
STAT1 P42224 1/20 0.38
HDAC6 Q9UBN7 1/20 0.37
TP53 P04637 2/20 0.37
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
DYRK1A Q13627 3/20 0.35
RIPK1 Q13546 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5538752 0.90 HSD17B10 (0.43) HSD17B10NPC1RAB9ASMN1; SMN2NFKB1
SCHEMBL5537849 0.88 TLR8 (0.44) HSD17B10NPC1RAB9ASMN1; SMN2NFKB1
SCHEMBL5545581 0.87 RAB9A (0.49) NPC1RAB9ASMN1; SMN2TP53DYRK1A
SCHEMBL5543821 0.86 NPC1 (0.47) HSD17B10NPC1RAB9ASMN1; SMN2NFKB1
SCHEMBL8185281 0.81 HSD17B10 (0.68) HSD17B10NPC1RAB9ASMN1; SMN2NFKB1
SCHEMBL5541764 0.80 HSD17B10 (0.49) HSD17B10NPC1RAB9ASMN1; SMN2NFKB1
SCHEMBL10358903 0.80 HSD17B10 (0.45) HSD17B10NPC1RAB9ASMN1; SMN2NFKB1
SCHEMBL5542728 0.78 CASP3 (0.52) HSD17B10NPC1RAB9ASMN1; SMN2NFKB1
SCHEMBL5540542 0.76 CASP3 (0.48) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL28266928 0.76 KDM4E (0.63) NPC1RAB9ASMN1; SMN2NFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 HSD17B10 467/4885NPC1 2404/4885RAB9A 2824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.